Scarica l'app Stockscreener
0.698
4.98%
0.0331
Skye Bioscience Inc Borsa (SKYE) Ultime notizie
SKYE SEC FilingsSkye Bioscience 10-K, 10-Q, 8-K Forms - stocktitan.net
Earnings Miss: Whats the outlook for Skye Bioscience Incs sectorWeekly Investment Recap & High Accuracy Swing Trade Signals - baoquankhu1.vn
Skye Bioscience Signs Master Services Agreement With Lohman & Associates for Finance and Accounting Consulting - Minichart
Skye Bioscience reduces employee stock option exercise prices and appoints new CFO - Investing.com Australia
Skye Bioscience appoints John P. Sharp as CFO; Punit Dhillon and Tuan Diep have options repriced - TradingView
Skye Bioscience (SKYE) reprices 2.42M options and taps John Sharp as CFO - stocktitan.net
Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development - Bitget
Skye Bioscience doses first patient in nimacimab expansion study By Investing.com - Investing.com Australia
Skye Bioscience (SKYE) director receives 75,000 stock options at $0.615 strike - stocktitan.net
Skye Bioscience (SKYE) CSO updates option awards with repricing and new grants - stocktitan.net
Director at Skye Bioscience (NASDAQ: SKYE) receives 75,000-share stock option grant - stocktitan.net
[Form 3/A] Skye Bioscience, Inc. Amended Initial Statement of Beneficial Ownership - stocktitan.net
Skye Bioscience (SKYE) director awarded 75,000 stock options at $0.6150 - stocktitan.net
Skye Bioscience (SKYE) director Paul A. Grayson receives 75,000 stock options - stocktitan.net
Director at Skye Bioscience (SKYE) awarded 75,000 stock options at $0.615 - stocktitan.net
Skye Bioscience (SKYE) COO receives repriced stock options - stocktitan.net
Skye Bioscience (SKYE) reprices CEO stock options to $0.615 strike - stocktitan.net
Skye Bioscience, Inc. initiates expansion study of nimacimab to assess exposure and safety - Traders Union
Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study - marketscreener.com
Skye Bioscience doses first patient in nimacimab expansion study - Investing.com
Skye tests higher nimacimab doses ahead of Phase 2b obesity combo - stocktitan.net
Skye Bioscience, Inc. advances nimacimab dosing to target CB1 pathway - Traders Union
SKYE PE Ratio & Valuation, Is SKYE Overvalued - Intellectia AI
Aug Wrap: How does Skye Bioscience Inc perform in inflationary periods2026 Technical Overview & AI Enhanced Trading Signals - baoquankhu1.vn
Skye Bioscience Faces Nasdaq Listing Compliance Deficiency Notice - The Globe and Mail
Skye Bioscience, Inc. Files Form 8-K Announcing Notice of Delisting or Failure to Satisfy Nasdaq Continued Listing Rule (March 2026) 5 - Minichart
Skye Bioscience receives Nasdaq notice for minimum bid price deficiency By Investing.com - Investing.com Australia
Skye Bioscience receives Nasdaq notice for minimum bid price deficiency - Investing.com
Skye Bioscience Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Nasdaq warns Skye Bioscience (SKYE) after shares stay under $1 minimum - Stock Titan
Skye Bioscience outlines 2026 milestones as nimacimab advances toward Phase IIb with new dosing strategy - MSN
Piper Sandler Sticks to Its Buy Rating for Skye Bioscience (SKYE) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Skye Bioscience (SKYE) and Sandoz Group Ltd (OtherSDZXF) - The Globe and Mail
Skye Bioscience Inc (SKYE) Q4 2025 Earnings Call Highlights: Pio - gurufocus.com
Cantor Fitzgerald reiterates Skye Bioscience stock rating at Neutral By Investing.com - Investing.com Canada
Citizens reiterates Skye Bioscience stock rating on weight loss data By Investing.com - Investing.com Canada
Skye Bioscience (SKYE) Advances Nimacimab Development with Promi - GuruFocus
Craig-Hallum Maintains SKYE BIOSCIENCE INC(SKYE.US) With Hold Rating - 富途牛牛
Skye Bioscience Q4 2025 Earnings Call Transcript - MarketBeat
SKYE: Additive weight loss and durable efficacy drive nimacimab's advancement as a GLP-1 add-on - TradingView
Skye Bioscience, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:SKYE) 2026-03-10 - Seeking Alpha
Earnings call transcript: Skye Bioscience Q4 2025 highlights clinical advancements - Investing.com
Skye Bioscience Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Skye (SKYE) Reinforces Nimacimab Strategy with Promising Data - GuruFocus
Q4 and full year results reveal momentum, Skye Bioscience, Inc. asserts - Traders Union
Skye Bioscience 2025 10-K: Net loss $(55.9M), Loss per share $(1.41) - TradingView
Skye Bioscience (NASDAQ: SKYE) highlights nimacimab obesity and metabolic pipeline - Stock Titan
Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - ChartMill
Skye Bioscience, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Skye Bioscience Q4 2025 earnings preview - MSN
A Peek at Skye Bioscience's Future Earnings - Benzinga
Skye Bioscience, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Skye confirms phase 2 data on nimacimab for obesity expected later this year - MSN
Growth Value: Will Skye Bioscience Inc benefit from government policyQuarterly Portfolio Review & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Market Recap: Can Skye Bioscience Inc weather a recessionEarnings Growth Summary & Risk Managed Investment Strategies - baoquankhu1.vn
Growth Report: What are the analyst revisions for Skye Bioscience IncIs KNSL stock a good investment in YEARVolume Spike & Low Volatility Stock Suggestions - baoquankhu1.vn
Does Skye Bioscience Inc have a competitive edgeJuly 2025 Catalysts & Low Drawdown Momentum Ideas - baoquankhu1.vn
Smart Money: Can Skye Bioscience Inc beat the S P 5002025 Stock Rankings & AI Forecasted Entry and Exit Points - baoquankhu1.vn
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):